Colchicine is a drugs well-known to many people. It has been round for years and is commonly used within the remedy of inflammatory circumstances resembling pericarditis, pores and skin circumstances and gout. Nevertheless, latest medical trials have centered on using colchicine as a instrument to scale back residual irritation in sufferers with continual coronary artery illness who’re already being handled with customary medical therapies resembling aspirin, statins, and ACE-inhibitors. That is thrilling to us for a number of causes however primarily in its illumination of the significance of irritation within the development of in any other case well-managed illness. Low-Dose Colchicine: One other instrument within the BDM toolbox
The mechanism of motion of colchicine entails mitigating irritation inside the atherosclerotic plaques, stabilizing weak lesions and thus lowering the danger of recurrent cardiovascular occasions. Colchicine is at present FDA-approved just for the remedy of recognized illness (secondary or tertiary prevention), not for main prevention.
A abstract of latest research: COLCOT Trial (2019): The Colchicine Cardiovascular Outcomes Trial was the primary to indicate a major discount in MACE (main cardiovascular occasions), together with coronary heart assaults and stroke, amongst sufferers with recognized coronary artery illness (CAD). On this trial, sufferers handled with lowdose colchicine (0.5mg/day) have been in comparison with placebo.
